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Abstract
Pseudomonas aeruginosa is a widespread opportunistic pathogen that causes 
bloodstream, urinary tract, burn wounds infections and is one of the largest 
pathogens that infect cystic fibrosis patients’ airways and can be life-threatening 
for P. aeruginosa infections. In addition, P. aeruginosa remains one of the most 
significant and difficult nosocomial pathogens to handle. Increasingly, multi-drug 
resistance (MDR) strains are identified and the option of therapy is often very 
limited in these cases, particularly when searching for antimicrobial combinations 
to treat serious infections. The fact that no new antimicrobial agents are active 
against the MDR strains of P. aeruginosa is an additional matter of concern. In recent 
decades, bacterial drug resistance has increased, but the rate of discovery of new 
antibiotics has decreased steadily. The fight for new, powerful antibacterial agents 
has therefore become a top priority. This chapter illustrates and explores the current 
state of several innovative therapeutic methods that can be further discussed in 
clinical practice in the treatment of P. aeruginosa infections.
Keywords: P. aeruginosa, drug resistance, alternative therapies, vaccine,  
phage therapy
1. Introduction
We are currently facing an international crisis with many troublesome aspects: 
new antibiotics are no longer being detected, resistance mechanisms are developing 
in almost all clinical isolates of bacteria, and the effective treatment of infections is 
hampered by recurrent infections caused by persistent bacteria. Antibiotic failure is 
one of the most worrying health issues worldwide [1]. Although resistance acquisi-
tion is a natural phenomenon, it is accelerated by antibiotic misuse, inadequate 
inspection and poorly regulated management of antibiotics have resulted in the 
appearance and spread of multidrug-resistant (MDR) bacteria abroad in clinical 
medicine and in the livestock industry [2, 3].
Empirical antibiotic treatment requires monotherapy and combination therapy 
for suspected cases of P. aeruginosa and reduces mortality in patients with serious 
P. aeruginosa infections [4, 5]. However, because of the ability of this bacterium to 
avoid many of the currently available antibiotics, treatment of P. aeruginosa infec-
tions has become a great challenge [6]. Recently, the World Health Organization 
(WHO) has identified carbapenem-resistant P. aeruginosa as one of three bacterial 
species with an urgent need for new antibiotics to be developed to treat infections 
[7]. In addition, inappropriate treatment use of antibiotics accelerates the produc-
tion of multidrug-resistant strains of P. aeruginosa, resulting in the ineffectiveness 
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of empirical antibiotic therapy against this microorganism [8]. Resistance to a 
range of antibiotics, including aminoglycosides, quinolones and β-lactams, is 
demonstrated by P. aeruginosa [9]. Generally, the main mechanisms of P. aeruginosa 
used to fight antibiotic attack can be divided into intrinsic, acquired and adaptive 
resistance. Low external membrane permeability, the expression of efflux pumps 
that remove antibiotics from the cell, and the development of antibiotic inactivat-
ing enzymes are part of the intrinsic resistance of P. aeruginosa. Either horizontal 
transfer of resistance genes or mutational modifications will achieve the acquired 
resistance of P. aeruginosa [10]. P. aeruginosa ‘s adaptive resistance requires the 
development of biofilm in the lungs of infected patients, where the biofilm func-
tions as a diffusion barrier to inhibit the access of antibiotics to bacterial cells [11].
The effectiveness and safety of murepavadin in the treatment of infections of 
the lower respiratory tract caused by P. aeruginosa (suspected or confirmed) in 
patients with ventilation-associated pneumonia or CF-unrelated bronchiectasis 
(Clinical Trials. gov identifiers NCT02096315 and NCT02096328) have been tested 
in two clinical trials. However, by July 17, 2019, the trials were stopped because in 
research participants who had obtained murepavadin, an unusually high level of 
renal failure had been found. This decision would not impact the production of 
an aerosolized formulation of murepavadin for topical use [12]. Murepavadin is a 
particular weapon against P. aeruginosa, which separates it from the broad pipe-
line of antimicrobial natural and synthetic peptides acting against multiple taxa, 
P. aeruginosa included. Recently, several novel peptides with broad antimicrobial 
activity have been identified, such as antimicrobial peptide DGL13K, Mel4 and 
melamine (Melimine and Mel4 are chimeric cationic peptides with broad-spectrum 
antimicrobial activity), Cecropin B, Lysine-based peptidomimetics (LBP-2), 
Truncated pseudin-2 analogs (Pse-T2), antimicrobial peptide, termed 6 K-F17 
(sequence: KKKKKK-AAFAAWAAFAA-NH2), Melittin-derived peptides (MDP1, 
MDP2) [13–20]. In addition, multidrug-tolerant persistent cells can form in the bio-
film that are capable of surviving antibiotic attack; in cystic fibrosis (CF) patients, 
these cells are responsible for prolonged and recurrent infections [21]. For patients 
whose infections are resistant to traditional antibiotics, the development of new 
antibiotics or alternative therapeutic methods for treating P. aeruginosa infections 
is urgently needed. In recent years, new antibiotics with novel modes of action have 
been investigated, as have new routes of administration and resistance to bacterial 
enzyme alteration. Compared to traditional antibiotics, some of these newer anti-
biotics demonstrate excellent in vitro antibacterial activity against P. aeruginosa as 
well as lower minimum inhibitory concentration (MIC) [22, 23]. Moreover, several 
novel non-antibiotic therapeutic approaches that are highly successful in destroying 
antibiotic resistant P. aeruginosa strains have been documented in recent studies 
[24]. These approaches include: antimicrobial peptides, phage therapy, inhibition 
of quorum sensing, iron chelation, the use of nanoparticles, probiotic and vaccine 
strategy. In order to combat P. aeruginosa infections, these therapeutic approaches 
may be used either as an alternative to or in conjunction with traditional antibiotic 
therapies.
2. Mechanisms of action of antimicrobial agents
There are six basic mechanisms of antimicrobial agents presented below:
1. Inhibition of microbial cell wall synthesis.
2. Inhibition of microbial cell membrane function.
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3. Inhibition of microbial protein synthesis.
4. Inhibition of microbial DNA synthesis.
5. Inhibition of microbial RNA synthesis.
6. Inhibition of microbial metabolic pathways.
2.1 Inhibition of microbial cell wall synthesis
An integral microbial structure responsible for the shape of the cell is the 
cell wall. In addition, because of the high cytoplasmic osmotic pressure, the cell 
wall prevents cell lysis and facilitates the anchoring of membrane components 
and extracellular proteins, such as adhesins [25]. Bacterial cell wall synthesis 
has perhaps become the target field most commonly exploited for antimicrobial 
production on the basis of the number of antimicrobial drugs in clinical usage. Due 
to the absence of equivalents in human biology, the components of the cell wall 
synthesis machinery are attractive antimicrobial targets, thus providing intrinsic 
objective selectivity. The cytoplasmic synthesis of building blocks composed of 
N-acetyl muramic acid (M) linked to N-acetyl glucosamine (G) with an attached 
pentapeptide (P) side chain (referred to as MGP subunits) comprises the sequen-
tial late steps in cell wall synthesis. The linkage of the MGP subunit to the lipid 
II molecule enables subsequent translocation to the outside or periplasmic space 
of the cell through the cytoplasmic membrane. By catalyzing glycosidic linkages 
between the M and G components of the MGP subunits, transglycosylase enzymes 
then assemble the MGP subunits into a linear backbone. An immature peptidogly-
can structure is constituted by linearly connected MGP subunits. Transpeptidase 
enzymes then work to cross-link pentaglycine bridges to the peptide side chains, in 
the process, the terminal 2 D-alanines of the peptide side chain are cleaved, creating 
the mature, lattice-like peptidoglycan that provides the form and osmotic stability 
of the bacterium [26]. β-lactam antibiotics, such as penicillins and cephalosporins, 
are the most widely used antimicrobials that prevent cell wall biosynthesis [27]. 
These β-lactam antibiotics interact directly with bacterial transpeptidases and 
inhibit them effectively. As transpeptidase inhibitors, β-lactams thus obstruct 
the transition from immature to mature peptidoglycan, so these enzymes are also 
referred to as penicillin-binding proteins (PBPs). Due to the stereochemical similar-
ity of the β-lactam moiety with the D-alanine-D-alanine substrate, they are capable 
of doing this. Transpeptidases form a lethal covalent penicilloyl enzyme complex in 
the presence of the drug, which helps to inhibit the usual transpeptidation reac-
tion. This results in peptidoglycan that is weakly cross-linked, which makes the 
 developing bacteria extremely susceptible to cell lysis and death [28].
2.2 Inhibition of microbial cell membrane function
Lipids, proteins and lipoproteins are essentially made of biological membranes. 
The cytoplasmic membrane for water, ions, nutrients and transport systems serves 
as a diffusion barrier. Most health workers now assume that membranes are a 
lipid matrix with uniformly distributed globular proteins to penetrate through the 
bilayer of the lipid. A number of antimicrobial agents may cause disorganization of 
the membrane. These agents can be categorized into cationic, anionic, and neutral 
agents. Polymyxin B and colistemethate (polymyxin E) are the best-known com-
pounds [29]. For several antimicrobial agents, the cytoplasmic membrane forms an 
important barrier.
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The mode of action of certain antimicrobial agents may be due to the ability of 
such medicines to increase membrane permeability, making it easier for them and 
other compounds to penetrate. Antibacterial cationic agents, increased permeabil-
ity of the outer membrane to the lysozyme and hydrophobic compounds has been 
identified, such as polymyxin B. The initial function of these antimicrobial agents is 
to interrupt the structure of the outer membrane, allowing the cell to join itself and 
other compounds and inhibit unique metabolic processes [30]. There are several 
cell-damaging properties of Polymixin B: (i) the surface charge, lipid composition 
and membrane structure are disturbed; (ii) the K+ gradient on the cytoplasmic 
membrane is dissipated; and (iii) the cytoplasmic membrane is depolarized. One 
of the key factors regulating bacterial exposure to polymixin B is the permeability 
of the external membrane to lipophilic compounds. Since polymixin B is bulkier 
than its displacement of inorganic divalent cations, in the presence of polymixin B, 
the packing order of lipopolysaccharides (LPS) is changed. This results in increased 
permeability of a variety of molecules to the outer membrane and also promotes 
polymixin B uptake (“self-promoted” uptake) [31].
2.3 Inhibition of microbial protein synthesis
Microbial protein synthesis inhibition a range of groups of antimicrobial 
agents work by inhibiting the synthesis of bacterial proteins (ribosome function). 
That include aminoglycosides, macrolides, tetracyclines, ketolides, lincosamides, 
streptogramins, chloramphenicol and oxazolidinones [26, 32]. The synthesis of 
microbial proteins is led by ribosomes in conjunction with cytoplasmic factors 
which, during the initiation phase, elongation phase and termination phases, bind 
transiently to particles. Microbial ribosomes contain 70S particles consisting of two 
50S and 30S subunits, which join at the initiation stage of the synthesis of proteins 
and split at the termination stage. In bacterial protein synthesis, antimicrobial 
agents block various steps by interfering with the work of either the cytoplasmic 
factors or the ribosomes. Inhibitors which bind to the ribosomal subunit of 30S 
primarily interfere with initiation, although some interfere with the pairing of the 
AA- tRNA anticodon with the mRNA codon, elongation is thus impaired. The steps 
involved in the elongation process interact with inhibitors that bind to the 50S ribo-
somal subunit or to elongation factors that are transiently connected to ribosomes at 
certain stages of the cycle.
Through binding to particular ribosomal subunits [33], aminoglycosides func-
tion. By inducing the development of aberrant, non-functional complexes as well as 
causing misreading, aminoglycoside-type drugs may combine with other binding 
sites on 30S ribosomes and destroy bacteria. Spectinomycin is an antimicrobial agent 
that is closely linked to the aminoglycosides of aminocylitol. It binds and is bacterio-
static but not bactericidal to a particular protein in the ribosome. Tetracyclines are 
other agents which bind to 30S ribosomes. These agents tend to inhibit aminoacyl 
tRNA binding to the A site of the bacterial ribosome. Tetracycline binding is tem-
porary, so it’s bacteriostatic for these agents. Nevertheless, a wide range of bacteria, 
chlamydias and mycoplasmas are inhibited and highly helpful agents [29]. There 
are three major groups of medicines that inhibit the ribosomal subunit of 50S. A 
bacteriostatic agent that inhibits both gram-positive and gram-negative bacteria is 
chloramphenicol. By binding to a peptidyltransferase enzyme on the 50S ribosome, 
it prevents peptide bond formation. Macrolides are large compounds of the lactone 
ring that bind to 50S ribosomes and tend to impair the reaction or translocation of 
peptidyltransferase, or both. Erythromycin, which inhibits gram-positive species 
and a few gram-negative species, such as haemophilus, mycoplasma, chlamydia and 
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legionella, is the most significant macrolide. Against many of these pathogens, new 
molecules including azithromycin and clarithromycin have greater activity than 
erythromycin. There is a similar activity site for lincinoids, the most important of 
which is clindamycin. Generally, macrolides and lincinoids are bacteriostatic and 
only inhibit the development of new peptide chains [29].
2.4 Inhibition of microbial DNA synthesis
The modulation of chromosomal supercoiling by topoisomerase-catalyzed 
strand breakage and rejoining reactions is needed for DNA synthesis, mRNA 
transcription and cell division [34]. Depending on whether they catalyze reactions 
involving transient breakage of one (type I) or both (type II) strands of DNA, DNA 
topoisomerase enzymes are classified into two groups, I and II [35]. The topologi-
cal state of DNA inside cells is regulated by topoisomerases and is important for 
the vital processes of protein translation and cell replication. The enzyme that 
negatively super-coils DNA in the presence of ATP is DNA gyrase, a type II DNA 
topoisomerase [36]. Moreover, in the absence of ATP, this enzyme plays a role in 
the catenation and decatenation reaction of a double-stranded DNA circle, resolves 
knots in DNA, and also relaxes supercoiled DNA negatively. As a result, for almost 
all cellular procedures involving duplex DNA, including replication, recombination 
and transcription, the enzyme is vital. It is unique to the prokaryotic kingdom and 
is essential to the organism’s survival. Thus, for antibacterial drugs, DNA gyrase 
remains an ideal and attractive target. The most effective DNA gyrase-targeted 
antimicrobial agents are quinolones. Nalidixic acid, a naphthyridone inadvertently 
discovered as a by-product during chloroquine synthesis, was the source of the 
compounds [37].
Quinolones are unique DNA-gyrase inhibitors. DNA gyrase reactions such as 
supercoiling and relaxation involving DNA breakage and reunion are inhibited by 
quinolones, specifically interfering with the DNA gyrase breakage-reunion reaction 
by interacting with subunit A (GyrA) [38]. Relatively poor antimicrobial activity 
is found in first-generation quinolones, nalidixic acid and oxolinic acid. However, 
the synthesis and improvement over many generations of fluoroquinolones, such as 
norfloxacin and ciprofloxacin (second generation), levofloxacin (third generation), 
and moxifloxacin and gemifloxacin (fourth generation), has resulted in a variety 
of potent antimicrobial agents [38]. Most bacterial pathogens possess an additional 
essential topoisomerase, topoisomerase I (Topo I), in addition to the type II topoi-
somerases. Topo I is architecturally and mechanistically distinct from gyrase and 
topoisomerase IV, and is an attractive candidate for new antibacterial chemotypes 
to be discovered as such [36].
2.5 Inhibition of microbial RNA synthesis
Rifamycins inhibit DNA-dependent transcription by binding the DNA-bound 
and effectively transcribing RNA polymerase with a high affinity to the β-subunit 
(coded by rpoB). In the channel formed by the RNA polymerase-DNA complex, 
from which the newly synthesized RNA strand emerges, the β- subunit is located. 
Rifamycins clearly require that RNA synthesis has not progressed beyond two ribo-
nucleotides being added; This is due to the drug molecule ‘s capacity to sterically 
inhibit the initialization of nascent RNA strands. It should be noted that rifamycins 
are not believed to work by blocking the RNA synthesis elongation stage, although 
a recently discovered class of RNA polymerase inhibitors (based on the CBR703 
compound) could inhibit elongation by modifying the enzyme allosterically [34].
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2.6 Inhibition of microbial metabolic pathways
By competitively blocking the biosynthesis of tetrahydrofolate, which acts as a 
carrier of one-carbon fragments and is required for the ultimate synthesis of DNA, 
RNA and bacterial cell wall proteins, trimethoprim and sulfonamides interfere 
with folic acid metabolism in the microbial cell. Bacteria and protozoan parasites 
typically lack a transport mechanism in order to extract preformed folic acid from 
their host, unlike mammals [29]. Most of these species, while some are capable of 
using exogenous thymidine, must synthesize folic acid, circumventing the need 
for metabolism of folic acid. The conversion of pteridine and p-aminobenzoic acid 
(PABA) to dihydrofolic acid by the pteridine synthetase enzyme is competitively 
inhibited by sulfonamides. Sulfonamides have a greater affinity for pteridine syn-
thetase than for PABA. Trimethoprim has a huge affinity (10,000 to 100,000 times 
greater than that of the mammalian enzyme) for bacterial dihydrofolate reductase; 
it inhibits tetrahydrofolate synthesis when bound to this enzyme [29].
3. Mechanisms of resistance to antimicrobial agents
The ability of an organism to overcome the action of an antimicrobial agent to 
which it was previously susceptible is a general definition of antimicrobial resis-
tance [39]. With the growing production of MDR strains (i.e. resistance to at least 
three antibiotics), nosocomial infection caused by antibiotic resistant P. aeruginosa 
has emerged as a major concern in clinical care settings [40]. Because of its outer 
membrane with low permeability (1/100 of the permeability of the outer membrane 
of E. coli), P. aeruginosa exhibits intrinsic resistance to various antimicrobial agents 
(β-lactam and penem group of antibiotics) [41, 42]. While several other processes 
are also responsible for their intrinsic resistance, including the efflux system that 
expels antibiotics from the cell’s bacteria and the production of inactivating enzyme 
antibiotics. This bacterium, however is a highly diverse pathogen capable of adapt-
ing to the conditions around it. When subjected to selective pressure from antibiot-
ics, the mediated reaction encourages bacterial survival and improves resistance to 
antibiotics [43–45].
The development of antibiotic resistance during host colonization of patients 
with CF has been confirmed, with P. aeruginosa strains developing and gaining 
resistance during antimicrobial therapy [46]. Studies have shown a clear link 
between increased applications of ciprofloxacin, with a growing incidence of 
strains resistant to ciprofloxacin [47]. Therefore the excessive use of antimicrobial 
agents is another factor associated with the rise in MDR-Psedomonas aeruginosa. 
This acquired resistance may be attributable to the effects of the mutational event 
or the acquisition by horizontal gene transfer of the resistance gene and may occur 
during the mutational event of antibiotic therapy, leading to over-expression of 
endogenous β-lactamases or efflux pump, specific porin expression [48].
3.1 Resistance to β-lactam
Inhibition of the synthesis of the bacterial peptidoglycan cell wall requires 
β-lactam antibiotics [39]. Penicillin, cephalosporin, carbapenem and monobactam 
are included in this class. These classes include piperacillin and ticarcillin (penicil-
lin), ceftazidime (cephalosporin 3rd generation), cefepime (cephalosporin 4th 
generation), aztreonam (monobactam), imipenem, meropenem and doripenem 
(carbapenems) are most powerful β-lactam widely used to treat P. aeruginosa is 
β-lactam [49]. These enzymes break the amide bond of the β-lactam ring through 
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resistance to the β-lactam mediated by the action of β-lactamases, rendering the 
antimicrobial ineffective. The expression of endogenous β-lactamases or the expres-
sion of acquired β-lactamases may be due to this inactivation of the drug. To date, 
hundreds of β-lactamases have been recognized and are distinguished by their sub-
strate specificity. There are four major groups of beta-lactamases known in P. aerugi-
nosa on the basis of Amber’s molecular classification system: A-D [50]. Through the 
serine-residue catalytic activity, classes A, C and D inactivate the β-lactams, while 
class B or metallo- β-lactamases (MBLs) require zinc for their action [51].
3.2 AmpC β-lactamase (Cephelosporinase)
In particular, the development of endogenous β-lactamase, such as chromosomal 
cephalosporinase (AmpC β-lactamase). A variety of β-lactams, such as benzyl peni-
cillin, narrow spectrum cephalosporin and imipenem, can be induced in P. aeruginosa. 
Naturally, P. aeruginosa is susceptible to carboxypenicillins, ceftazidime and aztreo-
nam, but it can develop resistance through a mutation in the gene that contributes 
to AmpC β-lactamase hyper-production [52, 53]. The enzyme is usually produced in 
small amounts (‘low-level’ expression), resistance to aminopenicillins and to most 
early cephalosporins is determined. P. aeruginosa produces an inducible chromosome-
coded AmpC β-lactamase (cephalosporinase) belonging to the Ambler-based 
molecular class C and the first functional group according to Bush et al. [54, 55].
However, production of chromosomal cephalosporin in P. aeruginosa, in the 
presence of inducing β-lactams (especially imipenem), can increase from 100 to 
1000 times [56]. β-lactamase inhibitors used in clinical practice, such as clavulanic 
acid, sulbactam and tazobactam, do not inhibit AmpC cephalosporinase function. 
β-lactamase of AmpC is encoded by the gene ampC [57, 58]. Several genes, includ-
ing ampR, ampG, and ampD, are involved in ampC gene induction. AmpR encodes 
a positive transcriptional regulator and this regulator is required for the induction 
of β-lactamase. AmpG, a transmembrane protein that functions as a permease for 
1,6-anhydromurapeptides, which are known to be the signal molecules involved 
in the induction of ampC, is the second gene involved. The third gene, ampD, 
encodes a cytosolic amidase of N-acetyl-anhydromuramyl-L-alanine that hydrolyses 
1,6-anhydromurapeptides, which functions as an ampC expression repressor. The 
4th chromosome, ampE, encodes the protein of the cytoplasmic membrane that 
serves as the molecule of the sensory transducer necessary for induction. Except for 
avibactam, the activity of this AmpC β-lactamase is not inhibited by commercially 
available β-lactam.
3.3 Class A carbenicillin hydrolysing β-lactamases
Four β-lactamases (PSE- of Pseudomonas specific enzyme) carbenicillin hydro-
lyzing enzymes were identified in P. aeruginosa: PSE-1 (CARB-2), PSE-4 (CARB-1), 
CARB-3 and CARB-4 [59]. These enzymes belong to the group of β-lactamases of 
molecular class A and include carboxypenicillins, ureidopenicillins and cefsulodine 
in their substrate profile. These enzymes belong to functional group 2c and molecu-
lar class A [60]. Commercially available β-lactam inhibitors, such as clavulanic acid, 
tazobactam, and sulbactam, can inhibit the activity of this β-lactamase [61].
3.4 Resistance to aminoglycoside
Aminoglycosides are a microbial protein synthesis inhibitor which act by bind-
ing to the ribosomal subunit of the bacterial 30S and interfering with the initiation 
of protein synthesis. Resistance to aminoglycosides in Pseudomonas is mediated by 
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transferable aminoglycoside modifying enzymes (AMEs), low permeability of the 
outer membrane, active efflux and, in rare cases, target modification [62–64].
3.5 Aminoglycoside-modifying enzymes
AMEs inactivate the aminoglycoside by adding the antibiotic molecule to a 
phosphate, adenyl or acetyl radical, and thus modified antibiotics minimize the 
binding affinity of the bacterial cell (30S ribosomal subunit) to its target [65, 66]. 
Aminoglycoside phosphoryl transferases (APHs), aminoglycoside adenylyl trans-
ferases (also known as nucleotidyltransferases) (AADs or ANTs) and aminoglyco-
side acetyltransferases (AACs) are three types of AMEs involved in aminoglycoside 
alteration. The following AMEs are most commonly expressed by P. aeruginosa: 
AAC(69)-II (resistant to gentamicin, tobramycin and netilmicin), AAC(3)-I (resis-
tant to gentamicin), AAC(3)-II (resistant to gentamicin, tobramycin and netilmi-
cin), (69)-I (resistant to tobramycin, netilmicin and amicacin) and ANT(29)-I 
(resistant to tobramicin and gentamicin) [67].
3.6 Low outer membrane permeability
Membrane impermeability or reduced permeability is a mechanism known to 
provide resistance to many antibiotic forms, including aminoglycosides, β-lactams 
and quinolones [68]. For instance, this resistance mechanism is often encountered 
in cystic fibrosis isolates that are continually under antibiotic attack. Several mecha-
nisms, such as lipopolysaccharide (LPS) modifications, alteration of membranous 
proteins involved in substratum absorption, and inactivation of enzymatic com-
plexes involved in the energetic membrane necessary for transport system activity, 
may cause membrane impermeability [69].
3.7 Active efflux pumps
The combination of low membrane permeability and active efflux pumps is 
partially due to the natural resistance of P. aeruginosa to many groups of antibiotics. 
P. aeruginosa’s efflux systems involved in antibiotic resistance belong to the family of 
resistance-nodulation-division (RND) [70]. In order to confer resistance to several 
antibiotics, four major efflux systems have been described: MexAB-OprM, MexCD-
OprJ, MexEF-OprN and MexXY-OprM. These systems consist of three proteins: (1) 
the efflux pump protein found in the cytoplasmic membrane (MexB, MexD, MexF 
and MexY), (2) the pore-acting outer membrane protein (OprM, OprJ and OprN) 
and (3) A protein in the periplasmic space that bridges the cytoplasmic and outer 
membrane proteins (MexA, MexC, MexE and MexX). In both natural and acquired 
resistance, MexAB-OprM and MexXY-OprM are active, whereas only the other two 
mechanisms are observed in cumulative resistance.
Acquired resistance is observed following mutations in the regulatory systems 
that can be caused by antibiotic pressure and that can confer resistance to all 
groups of antibiotics upon over-expression of these efflux systems. Polymyxins, 
except [69]. Resistance to multiple groups of antibiotics that are substrates of these 
efflux systems can be caused by exposure to a single antibiotic. Quinolones are 
substrates of all efflux systems and are an important trigger factor that can generate 
cross-resistance to efflux systems of several major classes of antibiotics, including 
β-lactams and aminoglycosides, for pseudomonal therapy [71]. It is understood that 
efflux systems confer a moderate degree of resistance, but they typically act simul-
taneously with other mechanisms of resistance, thus taking part in the high-level 
resistance that can be observed in P. aeruginosa.
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3.8 Target modification
Due to the low affinity of the drug to the bacterial ribosome, bacteria may be 
resistant to aminoglycosides. This can be achieved by 16S rRNA methylation by 
target modification. Various 16S rRNA methylases have been identified for P. aeru-
ginosa: RmtA, first reported in clinical isolates of P. aeruginosa resistant to aminogly-
cosides and conferred resistance to all parenterally administered aminoglycosides, 
including amicacin, tobramycin, isepamicin, kanamycin, arbecacin and gentami-
cin, secondary 16S rRNA methylases including RmtB, ArmA and RmtD [72].
3.9 Resistance to fluoroquinolones
Resistance to fluoroquinolones arises by mutation in the DNA gyrase or topoi-
somerase 1 V coding bacterial chromosome gene or by successful drug transport 
out of the cell [73]. Topoisomerase 1 V mutations can occur in gyrA / gyrB genes 
within the motif of the quinolone-resistant determinative region (QRDR), which is 
considered to be the active site of the enzyme. This contributes to the altered amino 
acid sequences of the subunits A and B, and hence to the altered topoisomerase 
II with a low affinity for quinolone molecules. As a result of point mutations in 
parC and parE genes encoding the ParC and ParE enzyme subunits, modifications 
of a secondary target (topoisomerase IV) occur. The over-expression of efflux 
includes other types of fluoroquinolone tolerance in Pseudomonas. Mutations in 
the nalB, nfxB and nfxC genes, resulting in overexpression of MexA-MexB-OprM, 
 MexC-MexD- OprJ and MexE- MexF- OprN fallowing efflux [74].
3.10 Biofilm-mediated resistance
A biofilm is an aggregate of microorganisms that bind to each other on a living 
or non-living surface and are embedded in an extracellular polymeric (EPS) matrix 
of self-produced substances, including exopolysaccharides, proteins, metabolites, 
and eDNA [75, 76]. The microbial cells grown in biofilms are less sensitive than 
the cells grown in free aqueous suspension to the antimicrobial agents and the host 
immune response [77]. Even bacteria that are deficient or lack protective muta-
tions in their intrinsic resistance, when they grow in a biofilm, they can become 
less susceptible to antibiotics [78]. The general mechanisms of biofilm-mediated 
resistance that protect bacteria from antibiotic attack include antibiotic penetration 
prevention, altered microenvironment that induces slow biofilm cell growth, adap-
tive stress response induction, and differentiation of persistent cells [78–80].
P. aeruginosa causes chronic lung infections in CF patients and, through the 
production of DNA, proteins and exopolysaccharides, forms a biofilm on lung 
epithelial cell surfaces. The regulation of the formation of P. aeruginosa biofilm is 
multifactorial and mainly depends on quorum sensing systems, GacS / GacA and 
RetS / LadS two-component regulatory systems, exopolysaccharides and cdi- GMP 
[81]. Quorum sensing is a form of communication between bacterial cells and cells 
that regulates gene expression in response to changes in cell population density. 
P. aeruginosa has three major systems of quorum sensing, LasILasR, RhlI-RhlR, and 
PQS-MvfR, all of which contribute to mature and differentiated biofilm formation. 
During biofilm formation, P. aeruginosa undergoes numerous physiological and phe-
notypic changes [82]. For example, P. aeruginosa strains convert to a mucoid pheno-
type in CF chronic infection that displays upregulated production of alginate driven 
by the CF microenvironment, enabling the formation of colonies of biofilms. Due to 
its ability to show swarming and twitching motility, P. aeruginosa flagellum is impor-
tant for the initiation of biofilm formation. However, P. aeruginosa significantly 
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decreases flagellum expression after surface attachment and may also permanently 
lose the flagellum due to genetic mutations, reducing host immune response activa-
tion, allowing P. aeruginosa to evade immune detection and phagocytosis [83].
4. The global economic scenario of antibiotic resistance
It is still an immense global challenge to quantify the exact economic effect of 
resistant bacterial infections. Measuring the distribution of the disease associated 
with antibiotic resistance is a crucial prerequisite in this situation. A major economic 
burden for the entire world is antibiotic resistance. In the USA alone, 99,000 deaths are 
caused annually by antibiotic-resistant pathogen-associated hospital-acquired infec-
tions (HAIs). Approximately 50,000 Americans died in 2006 because of two popular 
HAIs, namely pneumonia and sepsis, costing the US economy around $8 billion [84]. 
Patients with antibiotic-resistant bacterial infections need to remain in the hospital 
for at least 13 days, creating an extra 8 million hospital days each year. There have been 
estimates of costs of up to $29,000 per patient infected for an antibiotic-resistant bac-
terial infection. In total, economic losses of approximately $ 20 billion were recorded 
in the US, while losses of approximately $35 billion per year were also recorded in 
terms of loss of productivity due to antibiotic resistance in health care systems [85].
A worst-case scenario could emerge in the coming future, according to the 
analysts of the Research and Development Corporation, a US non-profit global 
organization, where the planet could be left without any effective antimicrobial 
agent to treat bacterial infections. In this case, the global economic burden will 
be nearly $120 trillion ($3 trillion per annum), roughly equal to the entire actual 
annual health care budget of the United States. In general, the world population will 
be significantly affected: about 444 million people will succumb to infections as of 
2050, and birth rates will decrease rapidly in this scenario [86, 87]. These losses are 
calamitous, but these estimates reflect imperfect images of the economic costs of 
antibiotic resistance due to data limitations such as the inclusion of total conditions 
and resistance-susceptible diseases. The use of antibiotics in the livestock and food 
industries is another very critical trait of antimicrobial resistance (AMR), that was 
missing from the investigation. It is an important player in the rising AMR, likely 
causing its own projected economic losses. There is also a misappropriation of the 
use of antimicrobials as growth promoters in many developing countries. This 
activity has been outlawed in the European Union since 2006 [88, 89].
5. Novel alternative antimicrobial therapy for P. aeruginosa treatment
The overuse and misuse of antibiotics, which can lead to unwanted side effects 
and the production of drug-resistant bacterial strains, is a growing public health 
issue. The production of new antibiotics, in addition, is very limited and timely. The 
development of innovative therapeutic approaches to the treatment of infections 
with P. aeruginosa is therefore highly desirable and has received further interest over 
the past decade. These innovative therapeutic techniques, which involve antimicro-
bial peptides, phage therapy, inhibition of quorum sensing as well as the use of iron 
chelation, nanoparticles, probiotics and vaccine strategies.
5.1 Antimicrobial peptides
A number of species, from bacteria to animals, develop antimicrobial peptides 
(AMPs), also called host defense peptides, and they are active against a wide range 
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of microorganisms [90]. There is no complete understanding of the mode(s) of 
operation of AMPs. It is widely agreed that the cytoplasmic membrane is attacked by 
AMPs, leading to cell death [91]. AMPs have also been shown to possess anti-biofilm 
and immunomodulatory properties, in addition to antimicrobial activity, AMPs have 
been proposed as an alternative to traditional antibiotics to battle bacterial infections 
as a result of their broad-spectrum activity; AMPs exhibit rapid killing kinetics, low 
mediated resistance levels, and low host toxicity [92]. Many antimicrobial peptides, 
including GL13 K, LL-37, T9W, NLF20, cecropin P1, indolicidin, magainin II, nisin, 
ranalexin, melittin, and defensin, have demonstrated powerful antimicrobial effects 
of either direct bactericidal effects or biofilm disruption against P. aeruginosa [93]. 
In addition, by facilitating antibiotic absorption, disrupting biofilm formation or 
inhibiting bacterial quorum, some AMPs have demonstrated synergy with tradi-
tional antibiotics against several bacteria, including P. aeruginosa [94]. For instance, 
it has been shown that the clearance of P. aeruginosa biofilm was increased by a 
combination of GL13 K with tobramycin [95]. In 2017, Zheng et al. [96] observed 
that when combined with tetracycline in vitro, the minimum inhibitory concentra-
tion of cecropin A2 against clinical isolates of P. aeruginosa was reduced 8-fold.
5.2 Phage therapy
By inducing lysis, bacteriophages (phages) are viruses that infect and destroy 
bacteria [97]. In 1915, the British bacteriologist Frederick Twort first discovered 
phages. Two years later, Félix d’Herelle made a similar discovery independently in Paris 
and presented the phage therapy notion. With the advent of antibiotic therapy, phage 
therapy was abandoned in several countries, but has been continuously developed in 
Eastern European countries with facilities in Warsaw, Poland, and Tbilisi, Georgia [98]. 
Shotgun metagenome sequencing showed that there were antipseudomonal phages in 
the phage cocktails sold in pharmacies in Georgia and Russia [99]. The successful treat-
ment of infections with MDR P. aeruginosa has been reported in a few case reports from 
Belgium and the US, but has not gained broad acceptance in the Western world [100]. 
Phage therapy has many benefits, including replication at the infection site, high preci-
sion for attacking bacteria without effects on commensal flora, less side effects than 
other therapies, antibiotic-resistant bacteria bactericidal activity and simple admin-
istration [101]. The use of phages as an alternative to antibiotics has been extensively 
studied for the treatment of P. aeruginosa infections. There are 137 different phages that 
have been characterized to date that target the Pseudomonas genus [102]. Many in vitro 
and in vivo studies have been performed to test the efficacy of phages against chronic 
infections of P. aeruginosa. For instance, co-incubation of phage PA709 with the clinical 
strain P. aeruginosa 709 has been shown to significantly reduce the viability of P. aerugi-
nosa. Another research found that intranasal administration of P3-CHA bacteriophage 
to mice receiving a lethal dose of P. aeruginosa strain CHA substantially improved the 
rate of survival and reduced the bacterial load in the lungs [103].
Another benefit of phage therapy is that phages can be genetically modified 
as vehicles to transport bacteria with antimicrobial agents, thus increasing treat-
ment efficacy [104]. While phages have been shown to be successful in vitro and in 
animal models against bacterial infection, only a small number of phage therapy 
clinical trials have been performed to date. The reasons for this include: safety 
issues about post-treatment phage clearance and impurity of phage preparations; 
poor stability of phage preparations; and lack of knowledge of the comprehensive 
phage mode of action and bacterial resistance to phage growth [105]. In clinical 
trials, the use of phages against P. aeruginosa infections has been studied in patients 
with venous leg ulcers, burn wounds and otitis, and no adverse reactions have been 
identified during these clinical trials [106].
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5.3 Quorum sensing inhibition
Quorum sensing is a mechanism that enables bacteria to regulate the expression 
of genes in a manner based on cell density. To control virulence and biofilm forma-
tion, P. aeruginosa utilizes quorum sensing [107]. Las and Rhl are two major P. aeru-
ginosa quorum-sensing systems responsible for the synthesis of the signal molecules 
of N-acyl homoserine lactone (AHL), N-(3-oxododecanoyl)-L-homoserine lactone 
(3O-C12-HSL) and N-butanoyl-L-homoserine lactone (C4-HSL). 3O-C12-HSL and 
C4-HSL bind to and activate their LasR and RhlR cognate transcription factors, 
respectively, inducing the formation of biofilms and the expression of various viru-
lence factors, including elastase, proteases, pyocyanin, lectins, rhamnolipids, and 
toxins [108]. The third P. aeruginosa quorum-sensing system, PQSMvfR, has been 
reported to facilitate the formation of biofilms in addition to the LasI-LasR and 
RhlI-RhlR systems. This mechanism regulates the development of the Pseudomonas 
quinolone signal (PQS), 2-heptyl-3-hydroxy-4-quinolone, by the transcriptional 
regulator MvfR, also known as PqsR, by controlling the pqsABCDE operon. In 
addition, PqsA and PqsD proteins have been implicated in the development of 
biofilms [82].
A promising technique for treating P. aeruginosa infections is known to be the 
inhibition of quorum sensing. This approach is capable of preventing or decreas-
ing the formation of biofilms, reducing bacterial virulence and has a low risk of 
bacterial resistance growth. In addition, this strategy has a small scope, such that 
any unwanted inhibitory effects on beneficial bacteria are impossible. For the Las 
and Rhl systems, quorum sensing inhibitors may be either natural or synthetic 
and are capable of reducing the activity of AHL synthase, inhibiting the develop-
ment of AHL, degrading AHLs or competing for AHL receptor binding [109]. In 
recent years, the use of quorum sensing inhibitors for the treatment of infections 
with P. aeruginosa has been intensively studied. The carotenoid zeaxanthin, typi-
cally found in plants, algae and lichens, for example, reduced the formation of 
biofilms in P. aeruginosa by binding to the signal receptors for quorum sensing, lasR 
and RhlR, and blocking the expression of virulence genes, lasB and rhlA [110]. 
Flavonoids are a class of naturally developed plant metabolites that have acted as 
LasR and RhlR antagonists and substantially decreased their ability to bind to the 
P. aeruginosa promoters of quorum sensing-regulated genes [111].
5.4 Iron chelation
Iron is important for bacterial growth and is involved in a number of cellular 
processes, such as the production of electricity, the replication of DNA and the 
transport of electrons [112]. Compared to healthy people, the iron content of 
human sputum was found to be substantially elevated in CF patients, indicat-
ing that an increased amount of iron promotes chronic CF lung infection [113]. 
P. aeruginosa utilizes pyoverdine and pyochelin siderophores to obtain iron from 
the extracellular environment [114]. Therefore, a technique to fight P. aeruginosa 
infections is to limit the concentration of extracellular iron or disrupt iron uptake 
by P. aeruginosa. Several studies have related iron metabolism to the pathogenesis of 
chronic infections, indicating that iron analogues and chelators may work against 
P. aeruginosa as potential therapeutic agents. For example, iron chelators, 2,2′- 
dipyridyl (2DP), diethylenetriaminepentacetic acid (DTPA) and EDTA, have been 
reported to impair growth and biofilm formation of P. aeruginosa and have been 
more effective under anaerobic conditions [115].
Gallium is a nonredox iron III analog that disrupts the metabolism of bacterial 
iron by acting in several biological processes as an iron replacement, so it is a US 
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FDA-approved medication for cancer-associated hypercalcemia treatment [116]. 
In 2007, Kaneko et al., reported that gallium was able to inhibit the growth of P. 
aeruginosa, prevent the development of biofilms, and manifest excellent bacteri-
cidal activity in vitro by reducing the uptake of bacterial iron and repressing the 
synthesis of pyoverdine mediated by the transcriptional regulator PvdS. In addi-
tion, in mouse infection models, gallium has also been found to remove P. aeruginosa 
effectively.
5.5 Nanoparticles
Currently, a variety of diseases, including cancer and bacterial infectious 
diseases, have received significant attention from nanoparticles to treat them. 
Nanoparticles are small materials that have been used in a number of chemical, 
biological and biomedical applications, having a size of less than 100 nm and a 
large surface area to mass ratio [117]. The nanoparticles used for their antimicrobial 
activity are highly penetrable in the bacterial membranes, may interfere with the 
formation of biofilms, have several antimicrobial mechanisms, and are strong 
antibiotic carriers [118]. For the prevention of P. aeruginosa infections, metallic and 
antimicrobial agent-loaded nanoparticles have been extensively examined. Silver 
nanoparticles, for example, are powerful antimicrobial agents that generate silver 
ions responsible for the inhibition, like DNA synthesis, of bacterial enzymatic 
systems. Silver nanoparticles have shown important antimicrobial effects on the 
clinical strains of P. aeruginosa, killing P. aeruginosa effectively and inhibiting its in 
vitro growth. In addition, silver nanoparticles have demonstrated low mammalian 
cell cytotoxicity, although this requires more in vivo research [119].
Nanoparticles are capable of delivering antimicrobial agents such as antibiotics 
to bacteria, as described earlier. Kwon et al., developed porous silicon nanoparticles 
with a novel antimicrobial peptide fused with a synthetic bacterial toxin, contain-
ing membrane-interacting peptides. This engineered nanoparticle was discovered 
in a mouse model of P. aeruginosa lung infection to increase the survival rate and 
bacterial clearance. Moreover, it has been found that the binding of antibiotics to 
nanoparticle surfaces greatly improves the effectiveness of both antibiotics and 
nanoparticles. In this respect, silver ampicillin-attached nanoparticles have a higher 
rate of in vitro killing of ampicillin-resistant P. aeruginosa isolates compared to silver 
ampicillin-attached nanoparticles [120].
5.6 Probiotic as an alternative antimicrobial therapy
Probiotics are living microorganisms which, when ingested in appropriate quan-
tities, provide health benefits [121]. The majority of probiotic bacteria are gram-
positive, and their primary functions are related to intestinal tract health regulation 
and maintenance (e.g., Lactobacillus and Bifidobacterium) [122]. The probiotics in 
the intestines that colonize the human host are the most numerous. The commensal 
intestinal microbiome leads to enhanced infection tolerance, differentiation of 
the host immune system, and nutrient synthesis [123]. The probiotic Pediococcus 
acidilactici HW01 was studied against P. aeruginosa and observed decreased P. aeru-
ginosa motility as well as decreased pyocyanin development, decreased protease and 
rhamnolipid production, and decreased stainless steel surface biofilm formation. 
Another research conducted by Moraes et al., showed that Lactobacillus brevis and 
Bifidobacterium bifidum were effective against S. aureus biofilms grown on titanium 
discs. The findings showed a decrease in S. aureus growth on titanium discs when 
both probiotics were used, but L. brevis strains was shown to have the greatest 
inhibitory effect on biofilm formation.
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Recent studies by Xu et al. [124], have indicated that probiotics can be used 
by patients infected by COVID 19 to prevent secondary infections. There was 
intestinal microbial dysbiosis in some patients with COVID-19. In all patients, 
nutritional and gastrointestinal functions must be measured. To control the com-
position of the intestinal microbiota and reduce the risk of secondary infection 
due to bacterial translocation, nutritional support and application of probiotics 
was suggested.
5.7 Vaccine strategy
The concept of a vaccine strategy is to avoid infection until it can be produced. 
The production of vaccines aims to prevent and decrease infections of P. aeruginosa 
[125]. However, no approved vaccine against this pathogen is yet available. P. aeru-
ginosa antigens, which are responsible for pathogenesis, induce potent immune 
responses. LPS O-antigen, polysaccharide protein conjugates, outer membrane 
proteins OprF and OprI, type III secretion system portion PcrV, flagella, pili, DNA, 
live-attenuated P. aeruginosa and whole killed cells are possible candidates for 
P. aeruginosa vaccines [126]. Among the potential P. aeruginosa vaccines, phase III 
clinical trials in CF patients were performed only with the flagella vaccine and the 
recombinant vaccine IC43, containing OprF and OprI.
Related to the ability of this pathogen to undergo phenotypic changes in vari-
able environmental conditions, the existing vaccines for P. aeruginosa demonstrate 
poor efficacy in clinical trials. For example, P. aeruginosa strains downregulate the 
expression of highly immunogenic virulence factors in CF patients’ lungs, such 
as LPS O-antigen, type III secretion systems, flagella and pili [127]. In addition, 
impaired mechanisms of host protection often reduce vaccination effectiveness. 
Due to the CF lungs having an altered mucus layer, impaired phagocytosis, and 
dysregulated inflammatory responses, including aberrant cytokine and chemokine 
production, and reduced phagocyte recruitment, the lung microenvironment in CF 
patients has become a great challenge for effective vaccination [128].
6. Role of combination therapy versus monotherapy
Early administration of adequate antibiotic therapy was associated with a favor-
able clinical outcome, especially among critically ill patients with serious P. aerugi-
nosa infections [129]; on the other hand, delays in administering adequate antibiotic 
therapy were associated with a substantial increase in mortality. The progressive 
rise in antibiotic resistance in P. aeruginosa has been established in recent years as 
the key explanation for the inadequacy of antibiotics, with a negative effect on 
patient survival [130].
The evidence available indicates that the greatest advantage of combination 
therapy derives from an increased probability of selecting an appropriate agent 
during empirical therapy, rather than avoiding resistance during definitive therapy 
or benefiting from synergistic action in vitro. Therefore, researchers recommend 
early administration of a combination regimen when P. aeruginosa is suspected, fol-
lowed by a prompt de-escalation when the antimicrobial susceptibility test becomes 
available, to balance between early antibiotic administration and the risk of resis-
tance selection. An approach consisting of the prescription of an anti-pseudomonal 
beta-lactam (piperacillin / tazobactam, ceftolozane / tazobactam, ceftazidime, 
cefepime, or carbapenem) plus a second (aminoglycoside or fluoroquinolone) 
 anti-pseudomonal agent is encouraged.
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7. New antipseudomonal antibiotics
Related to the emergence of multidrug-resistant strains, traditional antibiotic 
therapies against P. aeruginosa infections have become increasingly ineffective. The 
use of various antibiotic combinations and the development of new antibiotics are 
existing therapeutic options for P. aeruginosa treatment. New antibiotics have been 
shown to be more effective in destroying P. aeruginosa and have a lower frequency of 
production of resistance compared to current antibiotics due to their novel modes 
of action, efficient delivery of drugs (e.g. inhaled antibiotics) and resistance to 
bacterial enzyme alteration. Novel antibiotics with action against P. aeruginosa have 
been available in Europe in recent years and others are in advanced stages of clinical 
development. In certain instances, indirect evidence indicates their possible superi-
ority over standard anti-pseudomonal regimes.
7.1 Doripenem
Doripenem is a new carbapenem antibiotic with wide spectrum activity against 
gram-negative and gram-positive bacteria by binding to penicillin-binding proteins 
by inhibiting bacterial cell wall synthesis; it has been approved for the treatment 
of complicated intra-abdominal infection and urinary tract infection by the US 
Food and Drug Administration (FDA) [131]. Except for the metallo-β-lactamases 
of class B, doripenem is resistant to hydrolysis by several β-lactamases. Importantly, 
compared to other carbapenem antibiotics such as meropenem and imipenem, the 
in vitro antibacterial activity of doripenem against the P. aeruginosa isolates from CF 
patients was found to be more active [132]. In addition, the effectiveness of doripe-
nem was tested in patients with P. aeruginosa ventilator-associated pneumonia, a 
phase III clinical trial of patients with P. aeruginosa ventilator-associated pneumonia 
found that patients treated with doripenem had higher rates of cure compared to 
patients treated with imipenem. Of note, headache, nausea, diarrhea, rash, and 
phlebitis are among the side effects of doripenem [133].
7.2 Plazomicin
Plazomicin is a semisynthetic aminoglycoside antibiotic of the next generation 
that is synthetically derived from the natural product sisomicin. A wide range of 
aminoglycoside modifying enzymes, but not 16S rRNA ribosomal methyltransfer-
ases, are able to resist plazomicin [134]. Plazomicin exhibits potent in vitro activity 
against both gram-negative and gram-positive bacterial pathogens and has an activ-
ity close to that of amikacin against strains of multidrug-resistant P. aeruginosa. In 
addition, Pankuch et al., reported in vitro synergistic activity of plazomicin against 
clinical isolates of P. aeruginosa in combination with cefepime, doripenem, imi-
penem or piperacillin-tazobactam and no antagonism was observed in this study, 
indicating that plazonmicin is a possible candidate for combination therapy in the 
treatment of infections with multidrug-resistant P. aeruginosa. Plazomicin can cause 
nephrotoxic and ototoxic effects that are mild to moderate [135].
7.3 POL7001
As a novel class of antibiotics against P. aeruginosa, protein epitope mimetic 
(PEM) molecules have emerged; some PEM molecules inhibit the transfer of LPS to 
the outer bacterial membrane [136]. A macrocycle molecule belonging to the PEM 
antibiotic family is POL7001. The efficacy of POL7001 was tested by Cigana et al., 
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both in vitro and in murine P. aeruginosa acute and chronic pneumonia models. 
They observed that P. aeruginosa multidrug-resistant isolates were susceptible 
to POL7001 in CF patients, and that POL7001-treated mice had substantially 
decreased bacterial burden and decreased levels of lung inflammation during 
acute and chronic P. aeruginosa infection. POL7001 as a novel therapeutic agent for 
potential clinical trials is indicated by the new mode of action, effective pulmonary 
delivery and potent in vitro and in vivo activity. The side effects of POL7001 have 
not yet been identified [137].
7.4 Arikayce ™
Arikayce™ has been approved by the FDA for the treatment of Mycobacterium 
avium complex (MAC) lung disease, and is a liposomal amikacin treatment. Clinical 
trials for this drug and its efficacy in the treatment of P. aeruginosa in patients with 
cystic fibrosis have been performed. While these are early phases and some experi-
ments would have to resolve the drawbacks of this compound in order to improve 
safety, some experimental clinical trials have been performed [138].
7.5 Ceftolozane-tazobactam
To resolve P. aeruginosa antimicrobial resistance mechanisms, such as changes 
in porine permeability and upregulation of efflux pumps, ceftolozane-tazobactam 
is being created. Due to a higher affinity for all essential PBPs, including PBP1b, 
PBP1c and PBP3, this drug has an intrinsically potent anti-pseudomonal effect 
[139]. Ceftolozane/ Tazobactam has been shown to have a strong in vitro activity 
against most strains of MDR P. aeruginosa [including strains developing extended- 
spectrum β-lactamase (ESBL) but not carbapenemase]. The therapeutic use of 
ceftolozane-tazobactam in complicated intra-abdominal and urinary tract infec-
tions has been suggested by the FDA [140]. In addition, a study is currently under-
way for the treatment of HAP, including ventilator-associated pneumonia (VAP). In 
71 percent of patients with MDR P. aeruginosa infections, evidence from real-world 
trials using ceftolozane-tazobactam for the treatment of MDR P. aeruginosa infec-
tions showed promising results.
7.6 Ceftazidime-avibactam
Ceftazidime-avibactam is a novel combination of β-lactam / BLI approved for 
the treatment of complicated urinary tract infections (UTIs) and complicated 
intra-abdominal infections by the Food and Drug Administration (FDA) and 
European Medicines Agency (EMA). In vitro studies have shown that the combina-
tion of ceftazidime-avibactam is highly effective against KPC- producing Klebsiella 
pneumoniae carbapenemase (KPCs), oxacillinase (OXA), extended- spectrum 
β-lactamases (ESBLs) and AmpC enzymes producing Enterobacteriaceae. The drug 
does not, however, have any action against metallo-beta β- lactamases (MBL, VIM 
and NDM) and avibactam does not have any improved activity against P. aerugi-
nosa [141]. In phase III research compared ceftazidime-avibactam to meropenem 
(NTC01808092), the efficacy of ceftazidime-avibactam against VAP was analyzed 
[142]. The predominant isolated baseline gram-negative pathogens were K. pneu-
moniae and P. aeruginosa, with 28% of patients possessing a non-susceptible isolate 
of 1% ceftazidime. 356 patients in the clinically evaluable population were treated 
with ceftazidime-avibactam and 370 with meropenem. The research met the 
non-inferiority criterion for ceftazidime-avibactam as there was no disparity in the 
outcome between the groups. In addition, the efficacy of ceftazidime-avibactam 
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was close to that of ceftazidime-susceptible pathogens against ceftazidime-non-
susceptible strains and was also comparable to meropenem.
7.7 Imipenem-cilastatin-relebactam
Relebactam is a β-lactamase inhibitor (BLI) diazabicyclooctane that inhibits 
β-lactamase class A and C activity, but has no activity against metallo-β-lactamase. 
It has been shown that the combination of imipenem-cilastatin with relebactam has 
synergistic activity against a broad range of MDR gram negative pathogens includ-
ing P. aeruginosa, KPC-producing K. pneumoniae and Enterobacter spp. [143]. This 
medication has been tested predominantly in patients with IAI, complicated UTI, 
and pyelonephritis, although a trial is currently underway in patients with HAP/ 
VAP. Some new medications have a small effect on P. aeruginosa, such as plazomy-
cin, meropenem-vaborbactam and aztreonam-avibactam [144].
8. Conclusions
Treatment of infections with P. aeruginosa continues to be significant chal-
lenging. Improving the early diagnosis and empirical treatment of serious P. 
aeruginosa infections is an urgent need. First, to quickly announce the detection 
and susceptibility results for Pseudomonas in blood cultures and other clinically 
important cultures, matrix-assisted-laser-desorption-ionization time-of-flight 
mass spectrometry (MALDI-TOF) and modern molecular techniques should be 
routinely introduced. However, in order to decide if such diagnostic methods have a 
real effect on hospitalization time and patient mortality, controlled trials would be 
required. Secondly, more studies are urgently required to classify patients at risk of 
infection with MDR P. aeruginosa (bloodstream infections, urinary tract infections) 
based on clinical risk factors. Ultimately, clinical response depends on factors such 
as underlying diseases, seriousness of infection, form of infection, adequate control 
of the source, and response to prior antibiotics. There is an immediate need to 
determine the true impact of the latest anti-Pseudomonas drugs recently approved 
for the treatment of these infections on patient outcomes. To date, however, due to 
high cost, side effects and safety issues, few of these newer methods have continued 
to clinical practice.
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